William Blair & Company’s Spyre Therapeutics SYRE Stock Holding History

William Blair & Company’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,412	Closed	-$17.5K	–	1862
2023 Q1	$17.5K	Sell	2,412 -652	-21%	-$7.15K	﹤0.01%	1692
2022 Q4	$34.5K	Hold	3,064	–	–	﹤0.01%	1622
2022 Q3	$40K	Hold	3,064	–	–	﹤0.01%	1626
2022 Q2	$39K	Hold	3,064	–	–	﹤0.01%	1654
2022 Q1	$176K	Hold	3,064	–	–	﹤0.01%	1549
2021 Q4	$364K	Buy	3,064 +976	+47%	+$154K	﹤0.01%	1342
2021 Q3	$415K	Hold	2,088	–	–	﹤0.01%	1227
2021 Q2	$363K	Hold	2,088	–	–	﹤0.01%	1274
2021 Q1	$413K	Hold	2,088	–	–	﹤0.01%	1206
2020 Q4	$411K	Hold	2,088	–	–	﹤0.01%	1148
2020 Q3	$370K	Hold	2,088	–	–	﹤0.01%	1058
2020 Q2	$483K	Buy	2,088 +1,000	+92%	+$190K	﹤0.01%	951
2020 Q1	$127K	Hold	1,088	–	–	﹤0.01%	1276
2019 Q4	$208K	Hold	1,088	–	–	﹤0.01%	1294
2019 Q3	$209K	Hold	1,088	–	–	﹤0.01%	1251
2019 Q2	$186K	Hold	1,088	–	–	﹤0.01%	1323
2019 Q1	$219K	Hold	1,088	–	–	﹤0.01%	1267
2018 Q4	$204K	Hold	1,088	–	–	﹤0.01%	1227
2018 Q3	$260K	Hold	1,088	–	–	﹤0.01%	1201
2018 Q2	$288K	Hold	1,088	–	–	﹤0.01%	1143
2018 Q1	$270K	Buy	1,088 +640	+143%	+$116K	﹤0.01%	1104
2017 Q4	$61K	Hold	448	–	–	﹤0.01%	1330
2017 Q3	$55K	Hold	448	–	–	﹤0.01%	1327
2017 Q2	$43K	Buy	+448	New	+$61.9K	﹤0.01%	1482

Other funds holding SYRE

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

William Blair & Company's SYRE Position: Q2 2023 in Review

William Blair & Company sold out of Spyre Therapeutics (SYRE) in Q2 2023, closing a stake of 2,412 shares — an estimated $17.5K sold.

William Blair & Company first reported a position in SYRE in Q2 2017 and held it in 24 quarters. The position peaked at $483K in Q2 2020. 43 funds tracked by Wall St. Rank hold SYRE as of Q2 2023.

William Blair & Company reported no remaining Spyre Therapeutics position as of Q2 2023 after selling out during the quarter.
William Blair & Company sold 2,412 Spyre Therapeutics shares in Q2 2023, an estimated $17.5K.
William Blair & Company first reported a position in Spyre Therapeutics in Q2 2017 and held it in 24 quarters.
William Blair & Company's Spyre Therapeutics position peaked at $483K in Q2 2020.
43 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2023.

Based on William Blair & Company's 13F filing for Q2 2023, filed 11 Aug 2023.